论文部分内容阅读
作者用第二代血管紧张素转换酶抑制剂(ACEI)——Benazepril(BNZ)治疗20例慢性肾小球肾炎患者,观察其对尿蛋白、全身和肾血流动力学的影响。20例患者中男15,女5,平均年龄35岁,都为原发性肾小球疾病,其中10例IgA肾病,4例膜增殖性肾小球肾炎,3例膜性肾小球病,2例局灶性肾小球硬化,1例膜性毛细血管性肾小球肾炎。全组患者血压正常(130/83±16/10mmHg),肾功能正常(Scr93±15umol/L,Ccr106±25ml/min),尿蛋白持续≥1g/24hr,血清蛋白≥60g/L,经肾活检光镜及免疫萤光检查证实诊断,无系统性疾病。BNZ的剂量为10mg1/日,治疗时间为三个月。结果20例患者尿蛋白减少1～84%(平均34%)。与安慰剂组相比,尿蛋白减少30%以上的10例为显效组,减少30%以下的10例为疗效不良组。前者原有血浆
The second generation of angiotensin-converting enzyme inhibitor (ACEI) - Benazepril (BNZ) treatment of 20 patients with chronic glomerulonephritis, and its effects on urinary protein, systemic and renal hemodynamics. 20 cases of male 15, female 5, average age 35 years old, are primary glomerular diseases, including 10 cases of IgA nephropathy, 4 cases of proliferative glomerulonephritis, 3 cases of membranous glomerulopathy, 2 cases of focal glomerulosclerosis, 1 case of membranous capillary glomerulonephritis. All patients had normal blood pressure (130/83 ± 16 / 10mmHg), normal renal function (Scr93 ± 15umol / L, Ccr106 ± 25ml / min), persistent urinary protein≥1g / 24hr, serum protein≥60g / L, Light microscopy and immunofluorescence confirmed the diagnosis, no systemic disease. BNZ dose of 10mg1 / day, the treatment time of three months. Results The urinary protein in 20 patients decreased by 1 ~ 84% (average 34%). Compared with the placebo group, 10 cases of urinary protein reduced more than 30% were markedly effective, and 10 cases of less than 30% were poorly effective. The former of the original plasma